Currently recruiting or soon-to-open randomized phase 3 trials enrolling first-line classic Hodgkin lymphoma
| Clinical trial (www.clinicaltrials.gov identifier) . | Inclusion/exclusion criteria . | Treatment arms . | Incorporates novel therapy? . | Expected primary completion date . |
|---|---|---|---|---|
| HD21 (NCT02661503) | Patients aged 18-60 y with stage IIB-IV disease | BEACOPP vs BRECADD | Brentuximab replaces bleomycin | March 2020 |
| COG AHOD1331 (NCT02166463) | Patients aged 2-22 y with stage IIB-IV disease | ABVE-PC vs BV-AVEPC | Brentuximab replaces bleomycin | December 2020 |
| EuroNet-PHL-C2 (NCT02684708) | Patients under 18 y with intermediate or advanced stage cHL | COPDAC-28 vs DECOPDAC-21 | No | September 2021 |
| FIL-Rouge (NCT03159897) | Patients aged 18-60 y with stage IIB-IV disease | Standard PET-adapted ABVD vs dose-dense ABVD without PET | No | January 2023 |
| S1826 (NCT03907488) | Patients aged 12 y or older with stage III-IV disease | BV-AVD vs nivolumab + AVD | One arm replaces bleomycin with brentuximab; the other arm replaces bleomycin with nivolumab | March 2024 |
| Clinical trial (www.clinicaltrials.gov identifier) . | Inclusion/exclusion criteria . | Treatment arms . | Incorporates novel therapy? . | Expected primary completion date . |
|---|---|---|---|---|
| HD21 (NCT02661503) | Patients aged 18-60 y with stage IIB-IV disease | BEACOPP vs BRECADD | Brentuximab replaces bleomycin | March 2020 |
| COG AHOD1331 (NCT02166463) | Patients aged 2-22 y with stage IIB-IV disease | ABVE-PC vs BV-AVEPC | Brentuximab replaces bleomycin | December 2020 |
| EuroNet-PHL-C2 (NCT02684708) | Patients under 18 y with intermediate or advanced stage cHL | COPDAC-28 vs DECOPDAC-21 | No | September 2021 |
| FIL-Rouge (NCT03159897) | Patients aged 18-60 y with stage IIB-IV disease | Standard PET-adapted ABVD vs dose-dense ABVD without PET | No | January 2023 |
| S1826 (NCT03907488) | Patients aged 12 y or older with stage III-IV disease | BV-AVD vs nivolumab + AVD | One arm replaces bleomycin with brentuximab; the other arm replaces bleomycin with nivolumab | March 2024 |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; AVD, doxorubicin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BRECADD, brentuximab vedotin, etoposide, doxorubicin, cyclophosphamide, dacarbazine, dexamethasone; BV, brentuximab vedotin; BV-AVEPC, brentuximab vedotin, doxorubicin, vincristine, etoposide, prednisone, cyclophosphamide; COPDDAC-28, cyclophosphamide, vincristine. prednisone, dacarbazine; DECOPDAC-21, dacarbazine, etoposide, doxorubicin, dyclophosphamide, vincristine, prednisone; PET, positron emission tomography.